A single-arm, open-label phase 2 trial of doxorubicin plus zalifrelimab, a CTLA-4 inhibitor, with balstilimab, a PD-1 inhibitor, in patients with advanced/metastatic soft tissue sarcomas

被引：0
|
作者：
Wilky, Breelyn A.
Maleddu, Alessandra
Mailhot, Anne
Cartwright, Chelsey
Gao, Dexiang
Tellez, Cristiam Moreno
Powers, Kyle
Kemp, Lindsey
Therrien, Nicholas
Patel, Jaymin M.
Grossman, Joseph Elan
O'Day, Steven
Elias, Anthony D.
机构：
[1] Univ Colorado Anschutz Med Campus, Aurora, CO USA
[2] Univ Colorado, Sch Med, Aurora, CO USA
[3] Univ Colorado, Canc Ctr, Aurora, CO USA
[4] Univ Colorado, Aurora, CO USA
[5] Univ Colorado Anschutz Med Campus, Denver, CO USA
[6] Agenus Inc, Boston, MA USA
[7] Agenus Inc, Lexington, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
11501
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Neoadjuvant PD-1 inhibitor (toripalimab) plus chemotherapy in patients with potentially resectable NSCLC: An open-label, single-arm, phase II trial
    Zhu, X.
    Sun, L.
    Song, N.
    Sun, F.
    Yang, J.
    Duan, L.
    Zhao, D.
    He, W.
    Luo, J.
    Zhang, H.
    Wu, C.
    Zhu, Y.
    Zhang, P.
    Jiang, G.
    ANNALS OF ONCOLOGY, 2021, 32 : S942 - S942
  • [2] Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study
    O'Malley, David M.
    Neffa, Maryna
    Monk, Bradley J.
    Melkadze, Tamar
    Huang, Marilyn
    Kryzhanivska, Anna
    Bulat, Iurie
    Meniawy, Tarek M.
    Bagameri, Andrea
    Wang, Edward W.
    de Speville Uribe, Bernard Doger
    Hegg, Roberto
    Feliu, Waldo Ortuzar
    Ancukiewicz, Marek
    Lugowska, Iwona
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (07) : 762 - 771
  • [3] Efficacy and safety of cadonilimab (PD-1/CTLA-4 bispecific) in combination with chemotherapy in anti-PD-1-resistant recurrent or metastatic nasopharyngeal carcinoma: a single-arm, open-label, phase 2 trial
    Jiang, Yaofei
    Bei, Weixin
    Wang, Lin
    Lu, Nian
    Xu, Cheng
    Liang, Hu
    Ke, Liangru
    Ye, Yanfang
    He, Shuiqing
    Dong, Shuhui
    Liu, Qin
    Zhang, Chuanrun
    Wang, Xuguang
    Xia, Weixiong
    Zhao, Chong
    Huang, Ying
    Xiang, Yanqun
    Liu, Guoying
    BMC MEDICINE, 2025, 23 (01):
  • [4] Pan-cancer efficacy and safety of anlotinib plus PD-1 inhibitor in refractory solid tumor: A single-arm, open-label, phase II trial
    Qin, Bao-Dong
    Jiao, Xiao-Dong
    Wang, Zhan
    Liu, Ke
    Wu, Ying
    Ling, Yan
    Chen, Shi-Qi
    Zhong, Xue
    Duan, Xiao-Peng
    Qin, Wen-Xing
    Xue, Lei
    Guo, Zhen-Hong
    Zang, Yuan-Sheng
    INTERNATIONAL JOURNAL OF CANCER, 2023, 153 (04) : 815 - 825
  • [5] Safety and effectiveness of neoadjuvant PD-1 inhibitor (toripalimab) plus chemotherapy in stage II–III NSCLC (LungMate 002): an open-label, single-arm, phase 2 trial
    Xinsheng Zhu
    Liangdong Sun
    Nan Song
    Wenxin He
    Boxiong Xie
    Junjie Hu
    Jing Zhang
    Jie Yang
    Jie Dai
    Dongliang Bian
    Haoran Xia
    Fenghuan Sun
    Anwen Xiong
    Jie Luo
    Lele Zhang
    Huansha Yu
    Ming Liu
    Hongcheng Liu
    Haifeng Wang
    Haiping Zhang
    Chang Chen
    Chunyan Wu
    Liang Duan
    Yuming Zhu
    Peng Zhang
    Gening Jiang
    BMC Medicine, 20
  • [6] An Open-Label, Single-Arm, Phase 2 Trial of the PoloLike Kinase Inhibitor Volasertib ( BI 6727) in Patients With Locally Advanced or Metastatic Urothelial Cancer
    Stadler, Walter M.
    Vaughn, David J.
    Sonpavde, Guru
    Vogelzang, Nicholas J.
    Tagawa, Scott T.
    Petrylak, Daniel P.
    Rosen, Peter
    Lin, Chia-Chi
    Mahoney, John
    Modi, Sanjiv
    Lee, Peter
    Ernstoff, Marc S.
    Su, Wu-Chou
    Spira, Alexander
    Pilz, Korinna
    Vinisko, Richard
    Schloss, Charles
    Fritsch, Holger
    Zhao, Charles
    Carducci, Michael A.
    CANCER, 2014, 120 (07) : 976 - 982
  • [7] Surufatinib plus toripalimab in patients with advanced solid tumors: a single-arm, open-label, phase 1 trial
    Cao, Yanshuo
    Lu, Ming
    Sun, Yu
    Gong, Jifang
    Li, Jie
    Lu, Zhihao
    Li, Jian
    Zhang, Xiaotian
    Li, Yan
    Peng, Zhi
    Zhou, Jun
    Wang, Xicheng
    Shen, Lin
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (02) : 779 - 789
  • [8] Surufatinib plus toripalimab in patients with advanced solid tumors: a single-arm, open-label, phase 1 trial
    Yanshuo Cao
    Ming Lu
    Yu Sun
    Jifang Gong
    Jie Li
    Zhihao Lu
    Jian Li
    Xiaotian Zhang
    Yan Li
    Zhi Peng
    Jun Zhou
    Xicheng Wang
    Lin Shen
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 779 - 789
  • [9] Safety and effectiveness of neoadjuvant PD-1 inhibitor (toripalimab) plus chemotherapy in stage II-III NSCLC (LungMate 002): an open-label, single-arm, phase 2 trial
    Zhu, Xinsheng
    Sun, Liangdong
    Song, Nan
    He, Wenxin
    Xie, Boxiong
    Hu, Junjie
    Zhang, Jing
    Yang, Jie
    Dai, Jie
    Bian, Dongliang
    Xia, Haoran
    Sun, Fenghuan
    Xiong, Anwen
    Luo, Jie
    Zhang, Lele
    Yu, Huansha
    Liu, Ming
    Liu, Hongcheng
    Wang, Haifeng
    Zhang, Haiping
    Chen, Chang
    Wu, Chunyan
    Duan, Liang
    Zhu, Yuming
    Zhang, Peng
    Jiang, Gening
    BMC MEDICINE, 2022, 20 (01)
  • [10] An open-label, single-arm, phase 2 study of the Aurora kinase A inhibitor alisertib in patients with advanced urothelial cancer
    Andrea Necchi
    Salvatore Lo Vullo
    Luigi Mariani
    Daniele Raggi
    Patrizia Giannatempo
    Giuseppina Calareso
    Elena Togliardi
    Flavio Crippa
    Nicola Di Genova
    Federica Perrone
    Maurizio Colecchia
    Biagio Paolini
    Giuseppe Pelosi
    Nicola Nicolai
    Giuseppe Procopio
    Roberto Salvioni
    Filippo G. De Braud
    Investigational New Drugs, 2016, 34 : 236 - 242
12345